Last reviewed · How we verify
NCT03760549
Study of the Safety and Immunogenicity of NasoVAX Extension
trial testing Subjects were administered NasoVAX high dose in Influenza in 8 participants. Completed in 18 February 2019.
18 February 2019
Quick facts
| Lead sponsor | Altimmune, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 21 January 2019 |
| Primary completion | 18 February 2019 |
| Estimated completion | 18 February 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Subjects were administered NasoVAX high dose — full drug profile →
Conditions studied
- Influenza — all drugs for Influenza →
Sponsor
Altimmune, Inc. — full company profile →
Who can join
Adults 18 to 50, any sex, with Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial.
Tasker S, Wight O'Rourke A, Suyundikov A, Jackson Booth PG, et al · · 2021 · cited 19× · PMID 33807649 · DOI 10.3390/vaccines9030224 -
Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications.
Mehta PP, Dhapte-Pawar VS. · · 2021 · cited 9× · PMID 33640363 · DOI 10.1016/j.amjms.2021.02.019
Verify or expand the search:
- PubMed search for NCT03760549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza
Currently open trials in the same condition.
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
Other Altimmune, Inc. trials
Trials by the same sponsor.
- NCT07009860 — RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated · Phase 2 · recruiting
- NCT05989711 — IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) · Phase 2 · completed
- NCT05295875 — Efficacy and Safety of ALT-801 in the Treatment of Obesity · Phase 2 · completed
- NCT05292911 — Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) · Phase 1 · completed
- NCT05134662 — ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03760549 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Altimmune, Inc.
- Last refreshed: 19 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03760549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing